Immunovant, Inc.
NASDAQ:IMVTBiotechnology
+$0.69 today
- Market cap
- $6.86B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
Volume 0.91M
Average 1.84M
IMVT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Immunovant, Inc.NASDAQ: IMVT
Selling, General & Admin · Q2 FY2027 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q2 FY2027 selling, general & admin of $19.14M rose 9.3% year over year, ahead of the -16.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 8.2% from the prior quarter. Over 3 fiscal years it compounded at +16.7% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $0 (-100.0%) for the fiscal year ending Mar 2027, a slowdown from the -1.3% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $19.14M+8.2% QoQ
- Last fiscal yearMar 2026
- $76.24M-1.3% YoY
- LTMSep 2026
- $69.54M-16.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.3% | -100.0% | -109.3 pp |
| 1 year | -1.3% | -100.0% | -98.7 pp |
| 3-year CAGR | +16.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2026
- 76.24M USD
- Year-over-year change
- -1.3%
- 4-year CAGR
- +8.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 76.24M | -1.3% |
| FY2025 | 2025-03-31 | 77.24M | +34.8% |
| FY2024 | 2024-03-31 | 57.28M | +19.3% |
| FY2023 | 2023-03-31 | 48.02M | -11.4% |
| FY2022 | 2022-03-31 | 54.23M | — |
Selling, General & Admin vs competitors
How IMVT compares with its peers on the latest reported figures
- IMVT's LTM Sep 2026 selling, general & admin of $69.54M is the 2nd highest of the 11 companies compared; the peer median is $36.07M.
- Its year-over-year change of -16.7% is the lowest of 11, against a peer median of +17.8%.
- Selling, general & admin amounts to 980.1% of revenue for IMVT, versus a peer median of 33.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $313.76M | +50.7% | +34.4% | 34.9% | |
| LTM Sep 2026 | $69.54M | -16.7% | +16.7% | 980.1% | |
| LTM Mar 2026 | $62.81M | +42.2% | +11.5% | 27.0% | |
| LTM Mar 2026 | $57.81M | +55.3% | +58.0% | — | |
| LTM Mar 2026 | $52.28M | -5.2% | +10.5% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $39.39M | +37.0% | — | — |
| LTM Mar 2026 | $32.75M | -0.8% | +0.8% | — | |
| LTM Mar 2026 | $28.39M | -5.3% | +25.8% | — | |
| LTM Mar 2026 | $23.53M | +30.1% | +11.7% | — | |
| LTM Mar 2026 | $22.58M | +5.5% | -4.4% | 269.8% | |
| LTM Mar 2026 | $17.08M | -4.8% | +20.7% | 31.8% | |
| Peer median (excluding IMVT) | $36.07M | +17.8% | +11.7% | 33.4% | |
Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 101.81M | 160.26M | 212.93M | 360.92M | 456.66M |
| Selling, General & Admin | 54.23M | 48.02M | 57.28M | 77.24M | 76.24M |
| Operating Expenses | 156.03M | 208.28M | 270.21M | 438.15M | 532.9M |
| Depreciation & Amortization | 126K | 193K | 231K | 377K | 409K |
| EBITDA | (156.69M) | (198.28M) | (258.54M) | (412.57M) | (504.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (156.03M) | (208.28M) | (270.21M) | (438.15M) | (532.9M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 7.58M | 24.95M | 24.73M | 25.33M |
| Interest Expense | 0 | 12.48M | 0 | 0 | 0 |
| Other Income / Expenses | (781K) | (2.68M) | 11.44M | 25.2M | 27.51M |
| Income Before Tax | (156.81M) | (210.95M) | (258.77M) | (412.95M) | (505.39M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (84K) | 9K | 567K | 891K | 215K |
| Net Income | (156.73M) | (210.96M) | (259.34M) | (413.84M) | (505.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| EPS (Diluted) | (1.43) | (1.71) | (1.88) | (2.73) | (2.77) |
| Weighted Avg Shares | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
| Weighted Avg Shares (Diluted) | 109.68M | 123.08M | 138.1M | 151.57M | 182.42M |
Immunovant, Inc.
NASDAQ:IMVT
Intrinsic Alpha fair value
Locked
Current Price
$33.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.